Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Page 20 Page 21 Page 22 Page 23 Page 24 Page 25 Page 26 Page 27 Page 28 Page 29 Page 30 Page 31 Page 323 FROM T H E PRE SIDE NT AND CHAIRMAN •  Passage of a two-year suspension of the medical device tax, marking a major milestone in AdvaMed’s six-year campaign to repeal this onerous tax. Suspension will save the industry nearly $2 billion annually and provide new funds for investment in innovation. •  House passage of the 21st Century Cures Act with a full slate of regulatory reform proposals, including an expedited pathway for breakthrough technologies. If enacted, these reforms will increase the efficiency and predictability of the FDA review process, and improve patient access to the best in medical progress. •  Repeal of the Sustainable Growth Rate formula for Medicare physician payments, eliminating the pressure point from repeated, temporary patches that caused Congress to look to our industry for offsets. The Association also worked with member companies, CMS and lawmakers to develop and advance coverage, coding and payment proposals for legislation to help accelerate patient access to next- generation treatments and cures as part of congressional innovation initiatives. •  World Trade Organization expansion of the 1996 Information Technology Agreement, responding to AdvaMed advocacy, thus eliminating burdensome tariffs on $10 billion worth of U.S. medical technology exports. •  AdvaMed development of a China Code of Ethics on appropriate industry interactions with health care providers in China, and numerous tools and awareness materials to assist members with implementation and compliance certification. AdvaMed also launched a compliance app for mobile devices, with features to assist industry interactions and discussions with health care providers on issues under the AdvaMed Code of Ethics and Physician Payments Sunshine law. •  AdvaMedDx development of comprehensive policy on reform­ ing diagnostics regulatory oversight. AdvaMedDx worked with FDA, key congressional committees and other stakeholders to advance oversight reform legislation, and also worked with CMS and other stakeholders to ensure effective implementation of diagnostics payment reform provisions of the Protecting Access to Medicare Act. •  Enactment of tax extenders legislation with provisions of particular benefit to the medtech industry’s emerging and early-growth enterprises, championed by AdvaMed Accel, including permanent extension of the R&D tax credit. •  And, finally, continued celebration of AdvaMed’s 40th anniversary year at our annual medtech conference and exhibition in San Diego, its first West Coast venue. AdvaMed 2015 attracted more than 2,300 attendees representing over 900 companies and stakeholder groups from 26 countries. Vincent A. Forlenza Chairman, President and Chief Executive Officer BD Chairman, AdvaMed Scott Whitaker President and Chief Executive Officer AdvaMed